Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions.

Our lead drug product candidates in clinical trials are designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. BA058 Injection is a daily subcutaneous injection of our novel synthetic peptide analog of human parathyroid hormone-related protein—or hPTHrP, a naturally occurring bone-building hormone—for the treatment of osteoporosis. The BA058 Microneedle Patch is a short wear-time, transdermal form of BA058 that may eliminate the need for daily injections and lead to better treatment compliance for patients.

Our long-term focus is on additional areas in women's health that include symptoms of menopause and age-related muscle loss. Our scientific leadership includes some of the world's leading experts in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.